Medizinische Universität Graz - Research portal
Selected Publication:
SHR Neuro Cancer Cardio Lipid Metab Microb
Creutzig, U; Zimmermann, M; Dworzak, M; Urban, C; Henze, G; Kremens, B; Lakomek, M; Bourquin, JP; Stary, J; Reinhardt, D.
Favourable outcome of patients with childhood acute promyelocytic leukaemia after treatment with reduced cumulative anthracycline doses.
Br J Haematol. 2010; 149(3): 399-409.
Doi: 10.1111/j.1365-2141.2010.08107.x
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Google Scholar
- Co-authors Med Uni Graz
- Urban Ernst-Christian
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Acute promyelocytic leukaemia (APL) treatment often includes high cumulative doses of anthracyclines, which can cause long-term cardiotoxicity. Here, we report the favourable outcome in 81 paediatric APL patients treated according to the consecutive acute myeloid leukaemia-Berlin/Frankfurt/Muenster (AML-BFM) trials -93/-98/-2004 with an anthracycline-cytarabine regimen in combination with all-trans-retinoid acid (ATRA). Outcomes achieved by treatment with a reduced cumulative anthracycline dose (350 mg/m(2)) were comparable to those reported for studies with higher doses. Five-year overall survival of the total cohort was 89 +/- 4% and event-free survival (pEFS) was 73 +/- 6%. Overall survival was similar when comparing AML-BFM trial periods (trial 93: 88 +/- 8%, 98: 85 +/- 7% and 2004: 94 +/- 8%, P((logrank)) = 0.63). Seventy-five (93%) patients achieved complete remission. Most fatal events occurred during the first 6 weeks of treatment. Long-term cardiotoxicity was observed in one patient. Two patients suffered from secondary haematological malignancies. Salvage treatment was effective in 7/9 patients (78%) with relapsed APL, who now are long-term survivors after second line combination treatment with arsenic trioxide (4/7 patients) and stem cell transplantation (5/7 patients). Our results demonstrate that - combined with ATRA - a lower cumulative anthracycline dose can be used safely to maintain high cure rates and promote the reduction of long-term sequelae, such as cardiotoxicity in APL patients.
- Find related publications in this database (using NLM MeSH Indexing)
- Adolescent -
- Anthracyclines - administration and dosage
- Antineoplastic Combined Chemotherapy Protocols - administration and dosage
- Cardiomyopathies - chemically induced
- Child -
- Child, Preschool -
- Cytarabine - administration and dosage
- Drug Administration Schedule -
- Female -
- Humans -
- Infant -
- Infant, Newborn -
- Leukemia, Promyelocytic, Acute - drug therapy
- Male -
- Neoplasms, Second Primary - chemically induced
- Recurrence -
- Survival Analysis -
- Treatment Outcome -
- Tretinoin - administration and dosage
- Find related publications in this database (Keywords)
- acute promyelocytic leukaemia
- children
- therapy
- anthracyclines
- cardiotoxicity